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CHAPTER I 
INTRODUCTION 
 
 
RNA interference (RNAi) by small interfering RNA (siRNA) has potential to be applied 
therapeutically to treat cancer or other pathologies whose etiology is related to aberrant gene 
overexpression [1]–[3].  siRNA is a class of 20-25 base pair double-stranded RNA that is able to 
cause post-transcriptional gene silencing following introduction and intracellular uptake [1].  
Following cellular uptake into the cytoplasm, the double-stranded siRNA is cleaved, and a single 
strand, known as the guide strand, loads onto the RNA-induced silencing complex (RISC), while 
the passenger strand is cleaved by Argonaute-2.  The RISC then uses the guide strand to identify 
and hybridize to the mRNA to be cleaved 
(Figure 1) [4]. In literature, siRNA has 
previously been injected directly to the eye for 
local gene silencing of human endothelial 
growth factor (VEGF) [5]. However, systemic 
administration of siRNA is limited by the 
small size of siRNA, which often leads to 
premature degradation by nucleases and renal 
clearance, while its negative charge provides a 
barrier to significant delivery through the 
cationic cellular surface.  Due to these poor 
pharmacokinetic properties, siRNA requires a 
Figure 1. Mechanism of RISC-induced cleavage of 
mRNA following transcription (adapted from Kanasty 
et al. [4]) 
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carrier for effective intracellular delivery [6].   
Cationic polymers that electrostatically condense siRNA have been widely studied as 
carriers that are able to protect siRNA from degradation while effectively penetrating the cell 
surface for intracellular delivery [7]–[9].  Many of these net positively charged carriers have 
demonstrated activity in vitro, but they often have poor hemocompatibility when injected 
intravenously in vivo, which can lead to unexpected toxicity [10].  Particles electrostatically 
assembled from cationic polymers and siRNA become unstable, nonspecifically bind with blood 
plasma proteins, which causes formation of erythrocyte aggregates that can accumulate within 
and block the pulmonary vasculature [11], [12].  Polyplexes of siRNA with cationic polymers 
can also be destabilized through interactions with anionic heparan sulfate in the glomerular 
basement membrane (GBM), leading to rapid renal excretion and hindered ability to generate 
RNAi within the intended tissue[13], [14]. 
 Here, a pH-responsive diblock 
copolymer-based micelle previously 
established for in vitro delivery of siRNA 
[15], [16] was utilized as the base delivery 
system.  This micelleplex system is self-
assembled from a diblock polymer consisting 
of a pH-responsive, endosomolytic core-
forming block composed of butyl methacrylate (BMA), propyl acrylic acid (PAA), and 
dimethylaminoethyl methacrylate (DMAEMA) and a corona-forming poly(DMAEMA) 
(pDMAEMA) block, which is positively charged at pH 7.4 and condenses anionic siRNA 
(Figure 2).  The micelle has a high positive surface charge, however, that hinders its ability to be 
Figure 2. Cationic diblock micelle-forming siRNA 
delivery polymer.  Figure adapted with permission 
from [23]. 
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directly translated for intravenous use in vivo.  In order to overcome this limitation, a series of 
micelles have been designed that leverage the same endosomolytic terpolymer core but that 
possess mixed coronas composed of DMAEMA and varied quantities and molecular weight 
poly(ethylene glycol) (PEG).  PEG was utilized because of its known beneficial effects on 
biocompatibility, stability, pharmacokinetics, and biodistribution of drug nanocarriers [17]–[21]. 
Here, these new micelles were characterized in vitro for stability, hemocompatibilty, 
cellular uptake, and siRNA delivery efficacy and in vivo in mouse models to determine tissue 
biodistribution and blood circulation half-life.  By optimizing the molecular weight and surface 
concentration of PEG on the corona of these mixed micelles, we have created a stable and 
effective siRNA carrier with a significantly improved blood circulation half-life that can be 
leveraged for enhanced permeability and retention (EPR) effect-based tumor delivery [22]. 
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CHAPTER II 
MATERIALS AND METHODS 
 
Materials 
All chemicals were purchased from Sigma-Aldrich Co. (St Louis, MO, USA) unless otherwise 
noted.  The 10 kDa methoxy-poly(ethylene glycol) (mPEG) was purchased from 
CreativePEGWorks (Salem, NC, USA), and the 20 kDa mPEG was purchased from JemKem 
USA (Plano, TX, USA).   Hiperfect transfection reagent was purchased from Qiagen (Hilden, 
Germany). 
 
Cell Culture 
MDA-MB-231 and NIH-3T3 cells were purchased from ATCC (Manassas, VA, USA). MDA-
MB-231 and RFP-231 (MDA-MB-231 cells that had been stably transfected with a firefly 
luciferase reporter gene) were cultured in DMEM (Gibco, Carlsbad, CA) with 10% FBS (Gibco, 
Carlsbad, CA) and 50 ug/mL gentamicin (Gibco, Carlsbad, CA).  NIH 3T3s were cultured in 
DMEM + 10% FBS and 1% P/S. 
 
Polymer synthesis and characterization 
All polymers were synthesized by reversible addition fragmentation chain transfer (RAFT) 
polymerization. 
Synthesis of 5k and 10k PEG macro chain transfer agent (macroCTA) 
The PEG macroCTAs were synthesized by adding dicyclohexylcarbodimide (DCC, 1 mmol) to a 
stirring solution of mono mPEG (250 umol), ethyl cyanovaleric trithiocarbonate (ECT, 500 
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umol) and 4-Dimethylaminopyridine (DMAP, 50 umol) in anhydrous dichloromethane. The 
reaction mixture was stirred for 48 hours under a nitrogen atmosphere. The precipitated 
cyclohexyl urea was removed by filtration, and the dichloromethane layer was concentrated and 
precipitated into diethyl ether twice. The precipitated polymer was washed three times with 
diethyl ether and dried under vacuum overnight. 1H nuclear magnetic resonance (NMR) spectra 
showed that 90% of the 10k PEG was conjugated with ECT, and 84% of the 5k PEG was 
conjugated with ECT.    
 
Synthesis of diblock PEG-b-(DMAEMA-co-PAA-co-BMA)  
The diblock polymer 5k PEG-b-(DMAEMA-co-PAA-co-BMA) (PEG-b-DPB) was synthesized 
via RAFT polymerization. The monomers were added to the 5k PEG macroCTA at 
stoichiometric quantities of 50% BMA, 25% DMAEMA, and 25% PAA at a monomer to CTA 
molar ratio of 400.  The initiator azobisisobutyronitrile (AIBN) was added at a CTA to initiator 
molar ratio of 20 in a mixture of dioxane and DMF as the solvent.  The polymerization was 
stirred for 24 hours at 70°C under a nitrogen atmosphere.  The resulting polymer was 
precipitated in 50% ether and 50% pentane three times, followed by drying under vacuum 
overnight.  The same conditions were used to synthesize and precipitate the 10k PEG-b-DPB.   
The 20k PEG-b-DPB was synthesized by RAFT by adding monomers in a stoichiometric 
ratio of 50% BMA, 25% DMAEMA, and 25% PAA to the 20k PEG macroCTA at a monomer to 
CTA ratio of 800.  Initiator AIBN was added at a CTA to initiator ratio of 8.33.  Polymerization 
was stirred over 24 hours in dioxane and DMF under a nitrogen atmosphere.  The resulting 
polymer was precipitated in the same way as the 5k PEG-b-DPB and 10k PEG-b-DPB. 
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Synthesis of pDMAEMA macroCTA 
The pDMAEMA macroCTA was synthesized via RAFT polymerization as previously described 
[15], [23].  Briefly, DMAEMA monomer was added to the ECT at a monomer to CTA ratio of 
100, and the initiator AIBN was added at a CTA to initiator ratio of 10.  The reaction was stirred 
over 6 hours at 70°C in DMF under a nitrogen atmosphere.  The resulting polymer was 
precipitated in pentane three times and dried under vacuum overnight. 
 
Synthesis of diblock DMAEMA-b-(DMAEMA-co-PAA-co-BMA) 
The diblock polymer DMAEMA-b-(DMAEMA-co-PAA-co-BMA) (D-b-DPB) was synthesized 
via a RAFT polymerization as previously described [15], [23].  Briefly, monomers were added to 
pDMAEMA macroCTA at stoichiometric quantities of 50% BMA, 25% DMAEMA and 25% 
PAA at a monomer to CTA ratio of 250.  The initiator AIBN was added at a CTA to initiator 
ratio of 5.  Polymerization was stirred at 70°C for 24 hours under a nitrogen atmosphere.  The 
resulting polymer was precipitated in 50% ether and 50% pentane three times and dried 
overnight under vacuum.  It was then dissolved in a minimal volume of 100% ethanol, further 
diluted into dH2O, and purified through a PD10 desalting column (GE Healthcare).  The eluent 
was lyophilized. 
 
Polymer characterization 
To determine molecular composition of the polymers, 1H NMR was performed in CDCl3 using a 
Bruker 400 MHz spectrometer. To determine molecular weight and polydispersity, gel 
permeation chromatography (GPC) was performed on the polymers in filtered dimethyl 
formamide (DMF) containing 0.1 M lithium bromide (LiBr) on an Agilent Infinity GPC. The 
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dn/dc values used to calculate absolute molecular weight were determined on the same 
instrument by direct injections of polymer solutions into the RI detector.  
 
Micelle formation and characterization 
Micelles were formed by solvent exchange.  Lyophilized diblock polymers of the desired 
characteristics and stoichiometry were weighed out and dissolved together in a minimal volume 
of pure ethanol. PBS was then slowly added to the dissolved polymers using a syringe pump at a 
rate of 8 mL/hour.  The final micelle solution was 2 mg/ml and contained 1% ethanol.  Micelles 
were filtered through a 0.45 um syringe filter and dynamic light scattering (DLS) measurements 
were performed on a Malvern Zetasizer Nano-ZS (Malvern Instruments Ltd, Worcestershire, 
U.K). Zeta (ζ) potential was also determined on the same instrument. Transmission electron 
microscopy (TEM) images were acquired using a Philips CM20 HR-TEM (Philips, EO, 
Netherlands).  TEM samples were prepared by quickly adding a drop of 1 mg/ml micelle 
solution on a copper grid and staining the grid briefly with uranyl acetate.  The grid was then 
allowed to dry under vacuum overnight before imaging. 
 
siRNA loading determination by gel electrophoresis 
siRNA loading of micelles was determined by gel electrophoresis. Briefly, micelles were 
complexed with siRNA over a range of N+/P- charge ratios for roughly 1 hour. N+/P- ratios 
were determined by using the positive charge due to the pDMAEMA, which is assumed to be 
50% protonated at pH 7.4, divided by the negative charge due to 21 base pair, double-stranded 
siRNA. After siRNA complexation, micelles were mixed with loading dye and were run 
alongside a 20 base pair molecular ladder on a 2% agarose gel. 
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Red blood cell hemolysis assay 
A red blood cell hemolysis assay to determine endosomolytic behavior of the micelles was 
performed as previously described [24]. Briefly, varying concentrations of micelles were 
incubated with fresh anticoagulated human red blood cells suspended in a range of pHs that 
represent extracellular, early endosome, late endosome, and lysosome pH (7.4, 6.8, 6.2, and 5.6, 
respectively), in a 96 well plate for an hour at 37°C. After incubation, the plate was centrifuged 
at 500xg for 5 minutes. 100 uL of supernatant was transferred to a clear bottom 96 well plate and 
absorbance at 595 nm was determined on a plate reader (Tecan Group Ltd, Mannedorf, 
Switzerland). 
 
Whole blood interaction assay 
The hemocompatibility of the micelles was determined by performing a whole blood aggregation 
assay as previously described [25]. Micelles were complexed with Cy5-labeled double stranded 
DNA (dsDNA) (Sigma-Aldrich Co., St. Louis, MO, USA), used as a model molecule for double 
stranded siRNA, at an N+/P- ratio of 6. The complexes were then added to dilute human whole 
blood for a final siRNA concentration of 200 nM in a 96-well plate.  As a control, the micelles 
were also added to PBS for a final siRNA concentration of 200 nM.  The formulations were 
placed on a shaker for 5 minutes before incubation at 37°C for an hour. The plates were then 
centrifuged at 500xg for 5 minutes. 100 uL of supernatant from each well was transferred to a 
black, clear bottom 96-well plate and Cy5 fluorescence was measured on a plate reader (Tecan 
Group Ltd, Mannedorf, Switzerland).  
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Measurement of stability in presence of heparin 
Heparin sodium salt acts as a model for competing polyanions that are present in vivo and within 
cells.  Micelles were complexed with double stranded siRNA at an N+/P- ratio of 6 for an hour. 
The complexes were then added to a black, clear-bottom 96 well plate at a final concentration of 
100 nM with 250 U/L heparin sodium salt in PBS in a total volume of 100 uL. Dilute Quant-iT 
RiboGreen RNA Reagent (Life Technologies, Grand Island, NY, USA) was added per 
manufacturer’s instructions to the mixture for a total final volume of 200 uL.  RiboGreen 
fluorescence (excitation of 488 nm, emission of 520 nm) was measured over two hours on a plate 
reader (Tecan Group Ltd, Mannedorf, Switzerland), and percent siRNA released from the 
micelles was determined by calculating percent fluorescence normalized to fluorescence of an 
equivalent concentration of free siRNA. 
 
Assessment of siRNA protection from degradation 
The hyperchromic effect describes an observed increase in absorbance at 260 nm when nucleic 
material degrades.  This phenomenon was used to determine the micelles’ ability to protect 
siRNA against nuclease degradation as previously described [26], [27].  Micelles were 
complexed to double-stranded siRNA at a N+/P- ratio of 6.  The micelles were then diluted in 
100 uL of dH2O for a final siRNA concentration of 500 nM and placed in a small volume quartz 
cuvette.  Then, 300 nU of Riboshredder RNAse Blend (Epicentre, Madison, WI, USA) was 
added and absorbance at 260 nm was kinetically monitored for 20 minutes on a Cary 100 UV-vis 
spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). 
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Cellular uptake by flow cytometry 
Cellular uptake of the micelles by MDA-MB-231 mammary epithelial cells was determined by 
flow cytometry as previously described [28]. Briefly, MDA-MB-231 cells were seeded on 24-
well plate in media supplemented with 1% FBS and were allowed to adhere overnight. Micelles 
were complexed with AlexaFluor488-labeled dsDNA at an N+/P- ratio of 6 for an hour. Cells 
were then treated with micelleplexes at a dsDNA concentration of 100 nM for 6, 12, and 24 
hours. Immediately after treatment, cells were washed with PBS and trypsinized. Following 
trypsinization, cells were centrifuged and cell pellets were re-suspended in 0.05% trypan blue 
solution to quench extracellular fluorescence. Cell fluorescence was measured via flow 
cytometry (FACSCalibur, BD Biosciences, Franklin Lakes, NJ) and analyzed using FlowJo 
software. 
 
Cytotoxicity assessment 
Cellular viability was measured in luciferase-expressing NIH-3T3 cells (Luc-3T3s) after 
treatment with micelles. Luc-3T3 cells were seeded on a black, clear bottom 96-well plate and 
allowed to adhere overnight. Micelles were complexed with scrambled siRNA at a N+/P- ratio of 
6.  Cells were treated for 6, 12, and 24 hours at a concentration of 100 nM siRNA. Immediately 
following treatments, media was removed and cells were washed once with PBS.  Fresh media 
containing luciferin was added to the cells, and the bioluminescence was measured on the IVIS 
Imaging System (Xenogen Corporation, Alameda, CA, USA). 
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siRNA gene knockdown 
RFP-231 cells (MDA-MB-231 cells that were virally transfected to constitutively express 
luciferase) were seeded in a black, clear-bottom 96-well plate in media supplemented with 1% 
FBS and allowed to adhere overnight. Micelles were complexed with anti-luciferase siRNA 
(Ambion model #AM4629) at an N+/P- ratio of 6, and cells were treated with micelleplexes for 
6, 12, and 24 hours. At the end of the designated treatment times, cells were washed with PBS, 
fresh media containing 1% FBS was added, and the cells were incubated for an additional 48 
hours. Following incubation, media was replaced with luciferin-containing media and 
bioluminescence was measured using an IVIS Imaging System (Xenogen Corporation, Alameda, 
CA, USA). Bioluminescence data was normalized to total cellular protein as determined using a 
Bradford Assay (Bio-Rad Laboratories Inc., Hercules, CA, USA). 
 
In vivo half-life determination 
Micelles were complexed to IRDye800-labeled dsDNA for an hour at a N+/P- ratio of 6.  Five 
BALB/c mice (6-8 weeks old) (Charles Rivers Laboratories, Wilmington, MA, USA) were 
injected in the tail vein with 2 mg/kg (normalized to dsDNA dose) micelleplexes.  Blood was 
retro-orbitally collected at 5 and 10 minutes post-injection (not to exceed two collections per 
animal).  At 20 minutes post-injection, animals were sacrificed, and blood was immediately 
collected from the renal vein.  Collected blood was centrifuged at 500xg for 5 minutes, and 5 uL 
of plasma supernatant was collected and diluted into 95 uL dH2O.  Fluorescence was measured 
on a plate reader (Tecan Group Ltd., Mannedorf, Switzerland) at an excitation wavelength of 810 
+/- 2.5 nm and an emission wavelength of 790 +/- 5 nm.  A standard curve was produced by 
measuring the fluorescence of the complexes in dH2O over the range of 200% to 6.25% of initial 
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injected dose. This standard was utilized to calculate the percent of injected dose in each blood 
sample, and these calculated values were used to determine blood circulation half-life. 
 
In vivo biodistribution 
Animals were injected with dsDNA micelleplexes as stated for the determination of blood 
circulation half-life.  20 minutes post-injection, animals were sacrificed and organs of interest 
were excised.  Lungs, heart, spleen, liver, and kidneys were excised and fluorescently imaged on 
the IVIS Imaging System (Xenogen Corporation, Alameda, CA, USA).  The different organs 
were separated into regions of interest (ROI), and the total fluorescence in each region was 
quantified. 
 
Statistical Analysis 
All data are reported as mean +/- standard error of the mean (SEM). ANOVA was used for 
statistical analysis, and Tukey’s post-hoc test was used to determine pairwise significance based 
on an alpha value of 0.05. 
 
Ethics Statement 
All animals in the study were treated humanely under conditions outlined by National Health 
Institute (NIH).  Experiments performed on the animals were approved by Vanderbilt 
University’s Institutional Animal Care and Use Committee (IACUC).  Human blood was 
collected from anonymous donors following a protocol approved by the Vanderbilt Institutional 
Review Board (IRB). 
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CHAPTER III 
RESULTS AND DISCUSSION 
 
Polymer synthesis and characterization 
Four different diblock polymers were synthesized by RAFT polymerization.  All four polymers 
contained a hydrophobic, pH-responsive block consisting of approximately 50% BMA, 25% 
PAA, and 25% DMAEMA, with a second PEG or DMAEMA block (Table 1).  The hydrophobic 
block was approximately 20 kDa for all polymers except for the polymer containing the 20 kDa 
PEG, which has a longer hydrophobic block to ensure stable micelle formation despite the large 
hydrophillic block. 
The relative molar percentages of 5k PEG-b-DPB and D-b-DPB polymers were 
modulated to produce four mixed micelles: 100% D-b-DPB, 75% D-b-DPB / 25% PEG-b-DPB, 
50% D-b-DPB / 50% PEG-b-DPB and 25% D-b-DPB / 75% PEG-b-DPB.  These micelles will 
be referred to as 100D/no PEG, 75D/5k PEG, 50D/5k PEG, and 25D/5k PEG, respectively.  For 
these four mixed micelles, the only difference in composition was the relative quantity of PEG 
and DMAEMA in the corona.  Additionally, 50/50 micelles were made with the 10k and 20k 
PEG-containing PEG-b-DPB polymers mixed with the D-b-DPB to form 50D/10k PEG and 
50D/20k PEG micelles.   
Table 1. Molecular weight and composition of polymers used to create mixed micelles. 
Polymer Name Mn (g/mol) PDI 
Mn DMAEMA 
(g/mol) 
Mn PEG 
(g/mol) 
% BMA 
(core) 
% DMAEMA 
(core) 
% PAA 
(core) 
D-b-DPB 32370 1.1 12200 N/A 52 21 27 
5k PEG-b-DPB 26620 1.3 N/A 5000 45 25 30 
10k PEG-b-DPB 31080 1.7 N/A 10000 45 26 29 
20k PEG-b-DPB 55160 1.5 N/A 20000 47 28 25 
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Micelle characterization 
The 100D/no PEG, 75D/5k PEG, 50D/5k PEG, and 25D/5k PEG micelles all had hydrodynamic 
diameters of ~35 nm (Figure 3A).  However, micelle size increased for formulations with 
increased PEG molecular weight, ranging from 
35 nm (50D/5k PEG) to 65 nm (50D/20k 
PEG) (Figure 3B).  Generally, these diameters 
are in a useful range for EPR-based tumor 
delivery and are large enough to avoid renal 
clearance and small enough to avoid rapid 
macrophage clearance [29]. The ζ potential of 
the micelles is linearly correlated to the 
percent D-b-DPB in the 5 kDa PEG-containing 
mixed micelles, ranging from +17.6 mV 
(100D/no PEG) to +11.2 mV (75D/5k PEG) to 
+4.6 mV (50D/5k PEG) to  +0.1 mV (25D/5k PEG).  This trend suggests that the addition of 
PEG in the micelle corona causes surface charge shielding.  Similarly, as the PEG molecular 
weight increases in the 50D micelles, the ζ potential decreases from +4.6 mV to +2.2 mV to +0.5 
mV for the 5k, 10k, and 20k PEG-PDB polymers, respectively.  These data suggest that both 
relative molar percent and molecular weight of the PEG molecule can effectively shield micelle 
surface charge.   
TEM images reflect the size of the dehydrated mixed micelles that contain a collapsed 
corona (Figure 3C) [28].  Micelle diameter remains constant for the micelles containing the 5k 
PEG coronas with a diameter of approximately 20 nm.  Micelles with the 10 kDa and 20 kDa 
Figure 3. Chemicophysical characterization of mixed 
micelles.  (A) Size and ζ potential of mixed micelles 
containing variable molar percentage of PEG on the 
micelle corona, n = 3. (B) Size and ζ potential of 50D 
micelles containing varied lengths of PEG on the 
micelle corona, n = 3. (C) TEM of mixed micelles, 
reflecting the size of the hydrophobic core. 
 (A) Size and ζ potential of 
i l  ixtures PEG nd pDMAEMA in
the micelle coro a, n = 3. (B) Size and ζ potential of
50D micelles co taining varied lengths of PEG in 
corona, n = 3. (C) TEM of mixed micelles. 
 
 15 
PEG coronas have larger diameters of around 25 nm and 40 nm, respectively, which is consistent 
with the relative size increases measured with DLS (Figure 3C). 
 
 Micelle endosomal escape ability 
Hemolysis was performed to confirm the 
mixed micelles’ ability to escape the 
endosome upon cellular uptake (Figure 4).  
At pHs of 7.4 and 6.8, which represent 
cytoplasm and early endosome, the 
micelles show little to no hemolysis.  As 
the pH decreases to that representative of 
the late endosome and lysosome (pH 6.2 
and pH 5.6, respectively), percent 
hemolysis notably increases. This data 
indicates the potential for the mixed 
micelles to lyse the endosomal 
compartment before degradation in the late 
lysosome.  This ability is crucial for 
intracellular delivery of siRNA. 
 
 
 
Figure 4. Hemolysis experiments determine endosomal 
escape abilities of mixed micelles.  n = 3. (A) 5k PEG 
micelles with different molar compositions show hemolysis 
(B) 50D mixed micelles with different PEG lengths show 
hemolysis. 
 16 
Micelle hemocompatibilty, stability, and siRNA protection 
 To predict in vivo translatability of these 
mixed micelles, their stability was measured 
upon exposure to human whole blood.  Upon 
intravenous injection, cationic micelles are 
pre-disposed to adsorb blood serum proteins, 
which affects organ distribution and 
pharmacokinetics [30] and to form aggregates 
in the presence of serum proteins, which can 
cause an embolism within lung capillaries 
[12].  To model this phenomenon, Cy5-labeled 
dsDNA micelleplexes were incubated in fresh, 
anticoagulated whole human blood, and the 
percentage of micelles remaining in the plasma 
was quantified (Figure 5A and 5B) after 
incubation and a centrifugation step intended 
to separate out red blood cells and any micelle aggregates.  Increasing the ratio of the PEG-b-
DBP polymer relative to the D-b-DPB in the 5k PEG mixed micelles increased the percent of 
micelles remaining in the plasma supernatant; a significant portion (93%) of the 25D/5k PEG 
micelles remained in the plasma. PEG molecular weight also correlated with mixed micelle 
retention in the plasma supernatant, which ranged from 53% (50D/5k PEG) to 98% (50D/20k 
PEG).  These trends are likely due to the charge shielding and decreased zeta potential achieved 
Figure 5. Characterization of mixed micelle 
hemocompatibilty, protection of siRNA against 
nucleases, and micelle stability in presence of heparin.  
(A) Hemocompatibilty of mixed micelles containing 
varied percentage molar composition of PEG on the 
micelle corona indicates an increase in percentage 
PEG results in more desirable hemocompatibilty. (B) 
Hemocompatibilty of 50D micelles containing varied 
lengths of PEG on the micelle corona show that longer 
PEG results in more desirable hemocompatibilty. (C) 
siRNA protection of mixed micelles against nucleases 
indicates the micelles effectively protect cargo against 
nucleases.  
 17 
by PEG addition. This ex vivo screening suggests that micelles with the longest or highest 
surface concentration of PEG would be the most hemocompatible for in vivo studies.   
Another barrier to siRNA bioactivity in vivo is degradation and inactivation of siRNA by 
nucleases.  The hyperchromic effect is the increase in absorbance at 260 nm (A(260)) upon 
nucleic acid degradation.  siRNA protection by micelles was characterized by the hyperchromic 
effect during exposure to Riboshredder RNAse blend (Figure 5C).  All of the mixed micelle 
formulations effectively protected the siRNA against degradation in comparison with siRNA 
alone.  After 20 minutes, unformulated siRNA with the Riboshredder resulted in a 60% increase 
in A(260), while the siRNA formulated with the 100D/no PEG micelle exposed to Riboshredder 
resulted in the least protection among micelles, with an increase in A(260) of 20%.  All of the 
mixed micelles effectively protect the siRNA from nuclease degradation in vitro, which is 
potentially predictive of similar benefit in vivo.  
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Cellular uptake and gene knockdown  
Cellular uptake of Alexa488-labeled dsDNA mixed micelleplexes was evaluated by flow 
cytometry in MDA-MB-231 human mammary gland carcinoma cells (Figure 6A and Figure 6B).  
Regardless of mixed micelle stoichiometry, cellular uptake of dsDNA increased with treatment 
time.  Cellular uptake tended to inversely correlate with the ratio of PEG/pDMAEMA and the 
molecular weight of PEG in the corona, which is especially apparent at the 6-hour treatment 
Figure 6. Cellular uptake and gene knockdown after different treatment times.  (A) Relative cell 
uptake of mixed micelles containing varied ratios of PEG and DMAEMA in the corona. * p < 0.05 
(I am not clear what comparisons are being *’d for A) and & indicates significant difference (p < 
0.05) from 100D/no PEG. (B) Relative cell uptake of 50D micelles containing varied molecular 
weight of PEG in the corona. * p < 0.05.  (C) Percent knockdown of model gene luciferase 
achieved by luciferase siRNA delivered via mixed micelles containing varied amounts of 5k PEG 
on the corona.  * indicates significance (p < 0.05) from 100D/no PEG treatment; # indicates 
significance (p < 0.05) from 75D/5k PEG treatment; & indicates significance (p < 0.05) from 
50D/5k PEG treatment. (D) Percent knockdown of model gene luciferase using siRNA delivered 
in 50D mixed micelles containing varied molecular weight of PEG in the corona. 
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time.  Increasing the amount and molecular weight of the PEG also decreased zeta potential, 
which was likely a significant contributor to the differences in rate and extent of cellular uptake.  
This result is consistent with the presumption that electrostatic interactions between cationic 
delivery systems and the anionic cell surface promote internalization [7].  This relationship is 
especially apparent among different PEG lengths in the 50D formulations (Figure 6B).  The 
50D/5k PEG, 50D/10k PEG, and 50D/20k PEG micelles resulted in significantly different 
cellular uptake for each of the treatment times.  Finely tuning the stoichiometry and PEG 
molecular weight of the mixed micelles can be utilized to optimize the micelleplexes with an 
ideal combination of hemo-stability and cellular uptake / gene silencing bioactivity. 
RNAi was assessed in MDA-MB-231 cells that were lentivirally transduced to 
constitutively express luciferase.  In contrast to cellular uptake, gene knockdown did not 
correlate as strongly to the amount of pDMAEMA in the micelleplex corona (Figure 6C and 
Figure 6D).  PEG length in the 50D mixed micelles did not significantly influence gene 
knockdown, although cellular uptake was different among these micelles.  A number of events 
required for efficient RNAi occur between 
cellular uptake and protein-level knockdown 
by siRNA, and a key step is unpackaging 
and release of the siRNA so that it can load 
into the RISC and mediate gene silencing.  
We hypothesized that larger percent PEG 
and larger molecular weight PEG may be 
better released intracellularly due to reduced charge density and reduced valency of the 
interactions between pDMAEMA and siRNA. This may enable efficient gene silencing with 
Figure 7. Kinetics of siRNA decomplexation from micelles 
after exposure to 250 U/L heparin at an siRNA 
concentration of 100 nM. 
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these micelleplexes due to enhanced intracellular bioavailability, despite reduced rate of cell 
internalization [31].   
 
In support of this hypothesis, 
micelles were exposed to the polyanion 
heparin, and siRNA unpackaging was 
measured using RiboGreen (Figure 7).  
Micelles with higher surface ratio and with 
larger molecular weight PEG on the corona 
resulted in a more rapid and complete 
siRNA release over two hours.  This result 
is consistent with the hypothesis that the 
micelleplexes with the higher surface ratio 
and higher molecular weight PEG in the 
corona may release siRNA more efficiently 
intracellularly, resulting in a greater level 
of bioavailability / gene silencing relative 
to the quantity of siRNA internalized.   
 
Cytotoxicity evaluation 
 A cytocompatibility study was performed 
in NIH 3T3 fibroblasts retrovirally transduced to constitutively express luciferase (Figure 8).  
The 25D/5k PEG micelleplex at the maximum treatment time of 24 hours showed a significant 
Figure 8. Cytotoxicity evaluation of mixed micelles at 
different treatment times at a siRNA dose of 100 nM. (A) 
Cell viability of NIH 3T3 cells after treatment with mixed 
micelles containing varied percent molar composition of 
PEG on the micelle corona.  (B) Cell viability of NIH 3T3 
cells after treatment with mixed micelles containing varied 
lengths of PEG on the micelle corona. * signifies significant 
difference from No Treatment (p < 0.05), # signifies 
significant difference from 100D/no PEG (p < 0.05), and $ 
signifies significant difference from 75D/5k PEG (p < 0.05) 
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25% cytotoxicity relative to untreated cells, while none of the other formulations at any 
treatment time caused a significant reduction in viable cell number.  The mild toxicity of the 
25D/5k PEG micelleplex can be attributed to the higher total amount of polymer required to 
make this formulation with siRNA at a charge ratio of 6:1.  The charge ratio and siRNA 
concentration was held constant for all micelleplex formulations, but because the pD-b-PDB is 
the sole contributor to the charge ratio calculation, the total amount of polymer is increased as 
the % pDMAEMA is decreased in the micelleplex.  While the 25D/5k PEG micelle is favorable 
for its low ζ potential, it requires a high polymer dose.  This was motivation to expand the 
current study to also consider the larger molecular weight PEG molecules in order to achieve 
efficient charge shielding of the more cytocompatible 50D formulation.  
In vivo blood circulation half-life and biodistribution 
 Because of the desirable properties observed for the 50D micelles, they were carried forward for 
Figure 9. Effect of PEG length on corona on in vivo blood circulation half-life. (A) Concentration of 50D 
micelles with varied PEG lengths on the corona present in blood serum over time, n = 5. (B) Blood 
circulation half-life time values of 50D micelles with varied PEG lengths on corona. * represents 
significance (p < 0.05). 
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initial characterization in vivo.  Extended blood circulation half-life is critical for effective tumor 
accumulation of nanomaterials by the EPR effect [32], [33].  Previous studies using cationic 
polymeric siRNA carriers achieve blood circulation half-life values of <5 minutes [14], [34].  
Here, blood circulation half-life (t1/2) was determined by collecting blood at known times, and 
fitting the data to a one-variable exponential model that assumes starting dose (t = 0) in serum is 
100%, 𝑁 𝑡 = 100 ∗ 𝑒!!∗!" ! /!!/!.  Fitting the data to this model gives significantly different 
blood circulation half-lives of 4.6 minutes for 50D/5k PEG, 7.5 minutes for 50D/10k PEG, and 
17.7 minutes for 50D/20k PEG (Figure 9).  These data demonstrate that there is a strong 
dependence of blood circulation half-life on 50D micelle PEG molecular weight.  This also 
implies that in vivo half-life and function of structurally identical micelles can be modulated 
simply by altering PEG molecular weight in the corona.  The improved blood circulation half-
life of the 50D/20k PEG micelle may also 
result in improved tissue biodistribution 
following injection 
 Biodistribution of the micelleplexes 
was evaluated in the mice postmortem.  
Fluorescent imaging of organs (Figure 10B) 
confirmed that, as expected, a large 
percentage of the nanocarriers accumulated 
within the liver for all 50D mixed micelles.  
The 50D/5k PEG micelles had significantly 
greater biodistribution to the lungs, which is 
consistent with the ex vivo hemo-stability data 
Figure 10. In vivo tissue distribution of 50D micelles 
containing varied PEG lengths on the micelle corona 
20 minutes after injection in BALB/c mice. (A) Total 
fluorescence of the 50D micelles in 5 main organs, n = 
8. * represents significance (p < 0.05).  (B) 
Representative images of fluorescent biodistribution in 
5 main organs. 
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in Figure 2.  The 50D/5k PEG micelles resulted in a 2-fold increase in fluorescence in the lungs 
compared to the 50D/10k PEG micelles, and a 4-fold increase compared to the 50D/20k PEG 
micelles.  Increasing the PEG molecular weight minimized micelle biodistribution in the lungs, 
which would be predicted to decrease any potential for longer-term carrier toxicity in vivo.  
Similarly, increasing PEG molecular weight also affected biodistribution in the kidneys, and the 
50D/5k PEG micelleplexes had significantly increased distribution in the kidneys relative to the 
50D/10k PEG and the 50D/20k PEG micelleplexes.  This implies the 50D/5k PEG micelles may 
be more readily destabilized in the blood circulation, resulting in siRNA unpackaging and rapid 
renal clearance of the free molecules.  Tissue distribution was generally as expected for the 
50D/20k PEG micelleplexes, and their extended circulation time suggests that they may be ideal 
for tumor targeting in vivo.  
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CHAPTER IV 
CONCLUSIONS 
 
In vitro analysis was performed on a series of mixed micelles that contain varying surface 
concentrations and molecular weights of PEG on the corona to shield the micelles’ cationic 
charge.  The micelles that contained the highest surface concentration and the largest molecular 
weight PEG showed the least adsorption to blood plasma proteins ex vivo.  These particles also 
showed the lowest cellular uptake in MDA-MB-231 mammary gland carcinoma cells, likely due 
to the charge shielding that is achieved with the addition of PEG.  The series of mixed micelles 
demonstrated similar levels of gene silencing in vitro, implying different micelles undergo 
different intracellular processing following cellular uptake, likely due to their surface charge 
density.  
Ultimately, micelles with varying molecular weight PEG on the corona were chosen for 
further in vivo analysis based on their compatibility characteristics and their efficacy in vitro.  
Increased PEG molecular weight corresponded to decreased micelle accumulation in the kidneys 
and the lungs, which suggests a significant improvement in stability and decreased blood cell 
aggregation that leads to embolism, respectively.  Increased PEG length corresponded to a 
significantly longer blood circulation half-life.  Longer half-life is desirable because it allows the 
micelles to reach the intended tissue more readily without being prematurely cleared. 
  The 50D/20k PEG micelle demonstrates the potential for biocompatible siRNA 
delivery.  The long blood circulation half-life can be leveraged for delivery of therapeutic siRNA 
to tumors that are vascularized with the EPR effect.  Ongoing studies will assess the 50D/20k 
formulation for siRNA delivery to orthotropic breast cancer tumors that possess EPR 
 25 
characteristics.  It is expected that due to the micelle’s desirable properties, as evaluated in vitro 
and in vivo, it will preferentially distribute to the tumor and will effectively mediate RNAi in the 
tumor.  The present study has introduced a neutralized micelle that shows promise as a safe, 
stable in vivo siRNA delivery platform that will be evaluated further. 
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